Whanin Pharm (016580) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, Whanin Pharm (016580) reported revenue of 255.2 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
2025255.2 billion KRW13.0 billion KRW13.6 billion KRW[source]
2024259.6 billion KRW21.5 billion KRW23.4 billion KRW[source]
2023230.4 billion KRW30.2 billion KRW29.8 billion KRW[source]
2022198.9 billion KRW29.8 billion KRW23.7 billion KRW[source]
2021177.8 billion KRW31.3 billion KRW26.5 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
2025478.2 billion KRW57.6 billion KRW420.6 billion KRW[source]
2024423.6 billion KRW48.4 billion KRW375.2 billion KRW[source]
2023401.0 billion KRW42.9 billion KRW358.1 billion KRW[source]
2022368.8 billion KRW35.3 billion KRW333.5 billion KRW[source]
2021352.9 billion KRW35.9 billion KRW317.0 billion KRW[source]

Cash Flow

YearOperatingInvestingFinancingSource
20259.0 billion KRW4.7 billion KRW6.6 billion KRW[source]
202420.7 billion KRW-18.1 billion KRW-5.1 billion KRW[source]
202323.2 billion KRW-9.4 billion KRW-5.2 billion KRW[source]
202216.9 billion KRW-38.9 billion KRW-5.1 billion KRW[source]
202135.3 billion KRW-2.1 billion KRW-5.2 billion KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice